Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 240 participants.
Also called NCT01464476
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 240 participants
- Sponsor
- Registry
-
NCT01464476
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Belgium, Canada, Czechia, Denmark, France, Germany, Israel, Italy, Netherlands, Poland, Spain, Sweden
- Registry status
- Terminated
Technical summary
Registry record NCT01464476. Randomized; triple masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2013-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Azimilide on the Incidence of Cardiovascular Hospitalizations/Emergency Department Visits or Cardiovascular Death in Patients With an Implantable Cardioverter Defibrillator (ICD) (SHIELD-2)
- Acronym
- SHIELD-2
- Condition
- Arrhythmias, Cardiac
- Condition
- Heart Diseases
- Condition
- Cardiovascular Diseases
- Condition
- Implantable Cardioverter Defibrillator
- Intervention (Drug)
- Azimilide Dihydrochloride
- Intervention (Drug)
- Placebo
- Lead sponsor
- Forest Laboratories
Record details
- Record id
cardio:ct-nct01464476- Content hash
0eb57f241d0318b39f21b4d96f29e37f325af08d477c6df87e05f7bda79742a3